Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Abstract Background Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. Methods Pretreated non-s...

Full description

Bibliographic Details
Main Authors: Lorenza Landi, Federica D’Incà, Alain Gelibter, Rita Chiari, Francesco Grossi, Angelo Delmonte, Antonio Passaro, Diego Signorelli, Francesco Gelsomino, Domenico Galetta, Diana Giannarelli, Hector Soto Parra, Gabriele Minuti, Marcello Tiseo, Maria Rita Migliorino, Francesco Cognetti, Luca Toschi, Paolo Bidoli, Francovito Piantedosi, Luana Calabro’, Federico Cappuzzo
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Bone metastases
Nivolumab
Immunotherapy
PD-L1
Non-small-cell lung cancer
Online Access:http://link.springer.com/article/10.1186/s40425-019-0793-8

Internet

http://link.springer.com/article/10.1186/s40425-019-0793-8

Similar Items